MorphoSys Out-licenses Two Oncology Antibodies to HIBio

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)

Published: 20 Jun-2022

DOI: 10.3833/pdr.v2022.i6.2697     ISSN: 1756-7874

Section: Licensing



In an attempt to reorganise its oncology pipeline, MorphoSys has entered into a license agreement with Human Immunology Biosciences (HIBio) to develop and commercialise MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details